Pavilion Health Today
Supporting healthcare professionals to deliver the best patient care

SMC accepts three new medicines for use by NHS Scotland

The Scottish Medicines Consortium has published advice accepting three medicines. 

The Scottish Medicines Consortium (SMC) has published advice accepting three medicines. Eliglustat (Cerdelga) was accepted for the treatment of Gaucher disease. This is a rare inherited disorder which is debilitating, and if left untreated has a significant impact on quality of life due to a range of symptoms including excessive fatigue, spontaneous bleeding and bone pain. Through SMC’s Patient and Clinician Engagement (PACE) process for medicines used to treat very rare and end of life conditions, it was highlighted that current treatment involves patients or their carers administering fortnightly enzyme replacement therapy via intravenous infusion at home, which is both

---------------------------

This content is restricted to members of Pavilion Health Today. If you are an existing user, please log in. New users may register for free below.

Existing Users Log In
   
New User Registration
captcha
*Required field

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read more ...

Privacy & Cookies Policy